Inventiva Snnounces Results From The Phase II, LEGEND, Proof-Of-Concept Study Combining lanifibranor With Empagliflozin In Patients With MASH/NASH And T2D
Portfolio Pulse from Benzinga Newsdesk
Inventiva announced positive results from its Phase II LEGEND study on lanifibranor combined with empagliflozin in treating MASH/NASH and T2D. The study met its primary efficacy endpoint, showing significant reductions in HbA1c levels, liver injury markers, and hepatic steatosis. Both treatments were well tolerated with no safety concerns. Inventiva will host an investor webcast to discuss these results.
March 18, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's positive Phase II LEGEND study results for lanifibranor with empagliflozin in MASH/NASH and T2D treatment could boost investor confidence and potentially impact stock price positively.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. Given the significance of the LEGEND study's outcomes in addressing unmet medical needs in MASH/NASH and T2D, this news is likely to be viewed positively by the market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100